Environmental Risk Assessment Preparation for Pharmaceuticals
Synthesize pharmaceutical environmental data into FDA-compliant risk assessments
What You Can Do
This skill helps you synthesize complex environmental toxicology and fate data into cohesive, regulatory-quality Environmental Assessment narratives. You can organize hazard identification, exposure assessment, and risk characterization frameworks; integrate multi-study ecotoxicity evidence; cross-reference FDA/EMA/ICH M7 guidance; and identify data gaps—all while maintaining scientific rigor and compliance consistency required for NDAs, INDs, and BPCIs.
Features
Organizes data flow from hazard identification through exposure assessment to risk characterization
Consolidates ecotoxicity test results, environmental fate studies, and monitoring data into consistent narratives
Cross-references ICH M7, FDA Environmental Assessment Guidance, and EMA CHMP criteria to ensure section completeness
Drafts scientifically-grounded rationales for acute/chronic toxicity, persistence, and bioaccumulation classifications
Structures predicted environmental concentration (PEC) scenarios and exposure pathways into assessment narratives
Flags missing studies, inadequate biodegradation data, or exposure uncertainties requiring follow-up work
Links individual ecotoxicity reports and environmental monitoring results to specific EA sections with proper terminology
Example Output
Input: Raw data including fish acute toxicity (96-h LC₅₀), Daphnia chronic toxicity (21-d NOEC), soil biodegradation study (% mineralization at 28 days), LogPow, and predicted aquatic PEC from wastewater treatment.
Output Example 1 — Hazard Characterization Section: "The aquatic hazard profile was determined based on acute and chronic ecotoxicity studies in three trophic levels. Fish (Danio rerio) acute LC₅₀ of 2.3 mg/L and Daphnia magna 21-day NOEC of 0.15 mg/L indicate Category 1 acute aquatic hazard (meets ≤1 mg/L criterion). Chronic classification is Category 1 based on the NOEC/toxicity ratio to hazard thresholds per GHS Annex 1.A. Ready biodegradability testing showed 38% mineralization at 28 days, indicating non-rapid degradation and persistence concern."
Output Example 2 — Risk Characterization: "Environmental risk is low in aquatic compartments under predicted exposure scenarios. Predicted PEC in surface water (0.08 μg/L) derived from wastewater treatment plant modeling yields PEC/PNEC ratio of 0.002, indicating negligible acute risk. Bioaccumulation potential is limited (BCF <100, Log Kow 1.8), and terrestrial exposure pathways are not expected due to low soil mobility and rapid aqueous phase degradation."
What's Included
- SKILL.md: Full environmental risk assessment protocol with compliance frameworks
- EA Outline Template: Section-by-section structure for NDAs/INDs/BPCIs following FDA guidance
- Ecotoxicity Data Synthesis Checklist: Ensures all relevant studies (fish, Daphnia, algae, bacteria) are integrated
- ICH M7 Cross-Reference Table: Maps assessment elements to specific guideline requirements
- Hazard Classification Justification Framework: Structured format for GHS category rationales with threshold documentation
Who It's For
- Pharmaceutical toxicologists drafting Environmental Assessments for regulatory submissions
- Regulatory affairs professionals preparing NDA/IND environmental chapters
- Pre-clinical/safety scientists synthesizing ecotoxicity study data
- Environmental consultants supporting pharmaceutical companies in EA development
- Quality assurance reviewers validating Environmental Assessment completeness and consistency
Best For
- Organizing and structuring multi-study ecotoxicity datasets into coherent assessment narratives
- Drafting environmental chapters for FDA/EMA submissions with regulatory language and citations
- Synthesizing evidence for aquatic hazard classification and bioaccumulation assessments
- Identifying data gaps and recommending follow-up environmental studies
- Cross-referencing pharmaceutical environmental data against ICH M7 and FDA guidance requirements
You might also like
You can validate eCRF and paper CRF datasets against protocol-defined rules, automatically identify data discrepancies (missing fields, out-of-range values, date inconsistencies), generate structured Data Query Forms (DQFs) for site clarification, track resolution status, and create audit-ready compliance documentation that meets FDA 21 CFR Part 11 and GCP requirements. This workflow reduces manual validation time while ensuring 100% traceability and regulatory readiness for inspections.
by kody-w
You can design and execute bioanalytical method validations aligned with FDA Guidance for Industry and ICH guidelines, interpret complex validation data against regulatory acceptance criteria, and systematically troubleshoot analytical failures to identify root causes and corrective actions. This skill accelerates validation timelines by 20–30%, minimizes regulatory rework, and provides structured decision trees for problems that typically require expert consultation.
by kody-w
You can architect end-to-end bioinformatics analysis pipelines by translating your research question into algorithmic approaches, selecting and optimizing appropriate tools and parameters for your dataset, and validating results against biological expectations. This skill guides you through the complete decision tree from raw data to publication-ready interpretation, helping you avoid parameter overfitting, misinterpreted statistical thresholds, and algorithm selection errors that compromise research validity.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-wClaude reviews your injection mold, stamping die, or precision tool designs for manufacturability, cost reduction opportunities, and tolerance optimization. You provide CAD specifications, material details, and production volume—Claude identifies specific design modifications, material alternatives, and tolerance adjustments that reduce tooling complexity and unit costs without compromising performance.
by kody-w
You can upload or describe product designs and receive a comprehensive analysis of manufacturing feasibility, cost drivers, and prioritized optimization recommendations. The skill identifies design inefficiencies, material waste opportunities, assembly complexity challenges, and supply chain risks—giving you actionable steps to reduce costs and prevent production delays before they happen.
by kody-w
This skill organizes complex toxicology datasets, clinical adverse events, and mechanistic findings into structured, FDA/EMA-compliant safety narratives. You input raw safety data—adverse event summaries, laboratory results, animal study findings, vital signs—and receive draft safety summaries, detailed safety assessments, and expedited safety reports ready for regulatory submission. It handles IND applications, annual safety updates, clinical development safety overviews, and urgent safety communications with proper MedDRA coding and regulatory formatting.
by kody-w
You can design experiments with appropriate controls, replicate structures, and sample sizes before conducting any bench work. This skill helps you establish clear endpoints, identify confounding variables, select the right statistical tests, and create reproducible data collection protocols—preventing costly failed experiments and increasing publishability.
by kody-w